Solid Biosciences Inc. (SLDB) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, SLDB scores 27 and carries a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC -35%; FCF yield -22.98%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 5/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). The two weakest pillars, cash generation and insider conviction, indicate that the company is consuming cash without earnings support and that insider activity is not offering a confidence signal. The forensic balance sheet score is the strongest of the five, reflecting a Z-score in the reported range and a moderate Debt/Equity of 0.5, but a Piotroski F-Score of 1/9 signals weak financial health on the rubric's own terms. For a prospective investor, the upside case rests on the stock's price reaction to clinical and regulatory news rather than on current fundamentals, while valuation tradeoffs are unusually hard to assess because earnings-based multiples are not available in source data. The rating's message is that downside risk is elevated relative to the reward profile shown in these sources.

Per the SEC financials, both reported periods show zero revenue and zero net income, with operating losses of $-179.2M (FY 2025) and $-129.7M (FY 2024). Gross, operating, and net margins are each listed as 0% in the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, with Debt/Equity at 0.5. Cash declined from $80.2M to $59.9M across the two periods while free cash flow was negative in both.

Per the recent news feed, the most prominent items concern European Commission orphan designation for SGT-212 and continued progress in the FALCON trial in Friedreich's Ataxia; this item is flagged RED with a RISK WATCH impact label. Other items, flagged YELLOW with MARKET WIRE labels, include a H.C. Wainwright rating reiteration tied to the EU designation, a Benzinga after-market health care roundup, a Simply Wall St note on cash burn rate, and an ad-hoc-news.de report citing a stock valuation of USD 686.2 million alongside seven presented studies. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

• What are the company's products, lead programs, and revenue model, given that reported revenue is $0.0M in both periods?
• What is the company's cash runway at the reported FY 2025 burn rate relative to the $59.9M cash balance?
• What is the debt balance behind the Debt/Equity ratio of 0.5, given that debt is listed as N/A in the financials?
• What are the timelines and outcomes for the FALCON trial and the SGT-212 regulatory pathway?
• What drove the 52-week range of $3.79 to $11.45, and how does the current $6.39 price compare to that history?